VERAXA Biotech (NASDAQ: VRXA) announced new in vitro proof-of-concept data supporting its novel BiTAC-ADC technology platform, which is designed to improve precision in cancer treatment through tumor-restricted activation of therapeutic agents. The company reported that BiTAC-ADCs demonstrated the ability to distinguish between breast cancer and healthy cells and achieved dose-dependent killing of 3D tumor cell spheroids while minimizing toxicity through the use of separately delivered, systemically inactive precursor components.
These findings further validate the potential of the BiTAC-ADC platform and complement VERAXA's BiTAC-TCE technology, providing the company with two differentiated cancer therapy platforms that may be applicable across multiple solid tumor indications. Management plans to discuss partnering opportunities for both platforms at the BIO International Convention in San Diego from June 22-25, 2026. The full press release is available at https://ibn.fm/QiPhH.
VERAXA Biotech is building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs and other innovative formats. Powered by a suite of transformative technologies and guided by rigorous quality-by-design principles, the company is rapidly advancing its pipeline of ADCs and proprietary BiTAC formats into clinical development and beyond. VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL).
These results are particularly significant because they address a key challenge in oncology: delivering potent cancer-killing agents directly to tumor cells while sparing healthy tissue. By using separately delivered, systemically inactive precursor components that only become active in the tumor microenvironment, VERAXA's approach could reduce the severe side effects often associated with traditional chemotherapy and antibody-drug conjugates.
The BiTAC-ADC platform leverages bispecific antibodies that bind both a tumor antigen and a separate payload component, ensuring that the therapeutic agent is only assembled and activated at the tumor site. This conditional activation mechanism is designed to increase the therapeutic index, allowing for higher effective doses with lower systemic toxicity. The company believes this could expand the range of solid tumors treatable with antibody-based therapies.
VERAXA's management is actively seeking partnerships to advance both its BiTAC-ADC and BiTAC-TCE platforms. The company's pipeline includes several candidates targeting various solid tumors, and the new data support the potential for these technologies to become foundational in next-generation cancer therapy. Investors and industry observers will be watching for further developments as the company presents at the BIO Convention.
For more information and updates on VERAXA Biotech, visit the company's newsroom at https://ibn.fm/VRXA. Forward-looking statements in this article involve risks and uncertainties, and undue reliance should not be placed on them. The company undertakes no duty to update this information unless required by law.
